Evidence map›Paper›PMID 42581163›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study.

Felix Schmidt, Sofia-Maria Lider, Lisa McDougall, Christopher Eigler, Peter Bernhardt, Abdulrafee Mushaweh, Andreas Bauman, Melpomeni Fani, Emanuel Christ, Damian Wild

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Felix SchmidtClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Sofia-Maria LiderClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Lisa McDougallClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Christopher EiglerClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Peter BernhardtDepartment of Medical Radiation Sciences, Institution of Clinical Science, University of Gothenburg, Gothenburg, Sweden.
Abdulrafee MushawehClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Andreas BaumanClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Melpomeni FaniClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
Emanuel ChristENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland.
Damian WildClinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland. damian.wild@usb.ch.ORCID http://orcid.org/0000-0002-8135-5350

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with limited therapeutic options. Peptide receptor radionuclide therapy (PRRT) using somatostatin receptor (SSTR) antagonists (e.g. [

methodsIn this retrospective pilot study, 6 patients with mPPGLs received 1-2 cycles of [

resultsIntra-patient comparison showed that the median tumour absorbed dose per cycle was 1.3-fold higher (range 0.9-3.5) with [

conclusion[

Indexed as

DOTA-JR11Malignant pheochromocytoma and paragangliomaRadioligand therapySomatostatin receptor

Identifiers

PMID42581163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.